Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.
HCAbs, known for their fully human composition, have the potential to minimize immunogenicity and provide design flexibility for CAR-T therapies due to their compact structure and precise binding characteristics. This alliance aims to integrate Nona’s HCAb Harbour Mice platform and the direct CAR-function-based HCAb library screening platform, known as NonaCarFx, with Umoja’s VivoVec platform. The collaboration seeks to develop new in vivo CAR-T cell therapies, thereby broadening the scope of this cutting-edge treatment approach. Financial details of the agreement were not disclosed. – Flcube.com
